Targeting the Epigenome in Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Epigenetic alterations are key drivers in colorectal cancer (CRC) development, contributing to tumor plasticity and resistance to therapies.
• Current drugs targeting epigenetic modifiers show limited clinical success due to complex interactions within the epigenome and with genetic mutations and oncogenic pathways.

Purpose of the Study:

• To review recent advancements in epigenome-centered treatment strategies for colorectal cancer.
• To highlight the potential of epigenetic-associated therapies, emphasizing the need for biomarker integration and context-dependent reprogramming.

Main Methods:

• Literature review of recent advances in epigenetic therapies for CRC.
• Analysis of the interplay between epigenetic modifications, genetic mutations, and therapeutic resistance.

Main Results:

• Epigenetic drugs alone have limited efficacy in CRC treatment.
• Combination therapies involving epigenetic drugs, immune checkpoint inhibitors, monoclonal antibodies, and chemotherapy show promise.
• Biomarker integration and understanding cellular states are crucial for effective epigenetic therapy.

Conclusions:

• Epigenome-centered strategies are essential for overcoming CRC progression and drug resistance.
• Combination regimens targeting epigenetic vulnerabilities alongside other therapeutic modalities are recommended.
• Future epigenetic therapies require tailored approaches based on biomarkers and cellular context for optimal reprogramming.